Mepolizumab as a steroid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): Is a lower dose sufficient?

Conclusion: Our findings suggest that mepolizumab at a third of the recommended dose can achieve reasonable clinical efficacy in the long-term treatment of EGPA in some patients. Initiation of mepolizumab therapy in the early, eosinophilic phase of EGPA-which is characterized by asthma, marked blood eosinophilia, pulmonary infiltrates, and sinonasal abnormalities-may help to prevent the deleterious side-effects of long-term steroid use while reducing the cost of EGPA treatment. PMID: 32962455 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research